Claims for Patent: 8,394,765

Summary for Patent: 8,394,765

Title:	Methods of treating obesity with two different anti-obesity agents
Abstract:	Methods for treating obesity or obesity related disorders are disclosed. These methods include the use of anti-obesity agents directed to the forebrain in combination with anti-obesity agents directed to the hindbrain.
Inventor(s):	Roth; Jonathan D. (San Diego, CA), Anderson; Christen M. (Encinitas, CA), Baron; Alain D. (San Diego, CA)
Assignee:	Amylin Pharmaceuticals LLC (San Diego, CA) AstraZeneca Pharmaceuticals LP (Wilmington, DE)
Application Number:	11/940,317
Patent Claims:	1. A method of treating obesity in an obese leptin resistant subject comprising peripherally administering therapeutically effective amounts of two different anti-obesity agents, wherein one anti-obesity agent is pramlintide and one anti-obesity agent is metreleptin; and wherein the subject reduces body weight, thereby treating the obesity. 2. A method of reducing body weight in an obese leptin resistant subject comprising peripherally administering therapeutically effective amounts of two different anti-obesity agents, wherein one anti-obesity agent is pramlintide and one anti-obesity agent is metreleptin; and wherein the anti-obesity agents are administered in amounts effective to reduce the body weight of the subject. 3. The method according to claim 1 to 2, wherein the effective amount of the pramlintide and the effective amount of said metreleptin comprises an amount such that a greater amount of weight loss is achieved when said pramlintide is administered in combination with said metreleptin to said subject than the amount of weight loss achieved when either agent is administered alone. 4. The method of claim 1 or 2, wherein said pramlintide and said metreleptin are administered at the same time. 5. The method of claim 1 or 2, wherein said pramlintide and said metreleptin are mixed together. 6. The method according to claim 1 or 2 wherein body fat mass of the subject is reduced. 7. The method according to claim 1 or 2, wherein the subject has at least one condition selected from the group consisting of overweight, diabetes, insulin-resistance syndrome, nonalcoholic steatohepatitis, a cardiovascular disease, polycystic ovary syndrome, and metabolic syndrome. 8. The method according to claim 7, wherein the condition is being overweight. 9. The method according to claim 7, wherein the condition is diabetes. 10. The method according to claim 7, wherein the condition is insulin-resistance syndrome. 11. The method according to claim 7, wherein the condition is nonalcoholic steatohepatitis. 12. The method according to claim 7, wherein the condition is a cardiovascular disease. 13. The method according to claim 7, wherein the condition is polycystic ovary syndrome. 14. The method according to claim 7, wherein the condition is metabolic syndrome. 15. The method according to claim 1 or 2, wherein the subject is human. 16. The method according to claim 15, wherein the subject is a human adult female. 17. The method according to claim 1 or 2 wherein said subject reduces body weight by at least 5%. 18. The method according to claim 1 or 2 wherein said subject reduces body weight by at least 10%. 19. A method of treating obesity in an obese leptin resistant subject consisting essentially of peripherally administering therapeutically effective amounts of two different anti-obesity agents, wherein one anti-obesity agent is pramlintide and one anti-obesity agent is metreleptin; and wherein the subject reduces body weight, thereby treating the obesity. 20. A method of reducing body weight in an obese leptin resistant subject consisting essentially of peripherally administering therapeutically effective amount of two different anti-obesity agents, wherein one anti-obesity agent is pramlintide and one anti-obesity agent is metreleptin; and wherein the anti-obesity agents are administered in amounts effective to reduce the body weight of the subject. 21. The method according to claim 19 or 20, wherein the effective amount of said pramlintide and the effective amount of said metreleptin comprises and amount of such that a greater amount of weight loss is achieved when said pramlintide is administered in combination with said metreleptin to said subject than the amount of weight loss achieved when either agent is administered alone. 22. The method of claim 19 or 20, wherein said pramlintide and said metreleptin are administered at the same time. 23. The method of claim 19 or 20, wherein said pramlintide and said metreleptin are mixed together. 24. A method of treating obesity in an obese leptin resistant subject consisting of peripherally administering: a pharmaceutically formulation comprising a therapeutically effective amount of pramlintide; and a pharmaceutical formulation comprising a therapeutically effective amount of metreleptin; wherein the body weight of the subject is reduced, thereby treating the obesity. 25. The method according to claim 24, wherein the effective amount of said pramlintide and the effective amount of said metreleptin comprises an amount such that a greater amount of weight loss is achieved when said pramlintide is administered in combination with said metreleptin to said subject than the amount of weight loss achieved when either agent is administered alone. 26. The method of claim 24 wherein the subject is human. 27. The method of claim 24 or 26, wherein said pramlintide and said metreleptin are mixed together. 28. The method of claim 24 or 26, wherein said pramlintide and said metreleptin are administered at the same time. 29. A method of treating obesity in an obese leptin-resistant subject, consisting of: peripherally administering a pharmaceutically formulation comprising a therapeutically effective amount of pramlintide and a therapeutically effective amount of metreleptin; wherein the body weight of the subject is reduced, thereby treating the obesity. 30. A method of reducing body weight in an obese leptin-resistant subject consisting of: peripherally administering a pharmaceutically formulation comprising a therapeutically effective amount of pramlintide and a therapeutically effective amount of metreleptin; wherein the therapeutically effective amounts are effective to reduce the body weight of the subject. 31. The method of claim 29 wherein the subject is human. 32. The method of claim 30 wherein the subject is human. 33. The method according to any one of claims 29, 30, 31, and 32, wherein the therapeutically effective amount of said pramlintide and the effective amount of said metreleptin comprises an amount such that a greater amount of weight loss is achieved when said pramlintide is administered in combination with said metreleptin to said subject than the amount of weight loss achieved when either agent is administered alone.

Details for Patent 8,394,765

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Amryt Pharmaceuticals Dac	MYALEPT	metreleptin	For Injection	125390	02/24/2014		2024-11-01